Spots Global Cancer Trial Database for chronic myelogenous leukemia (cml)
Every month we try and update this database with for chronic myelogenous leukemia (cml) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Nilotinib, for Patients With CML-CP or CML-AP | NCT04518644 | Chronic Myeloge... | Nilotinib | 18 Years - 99 Years | Novartis | |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | NCT01050764 | Leukemia, Acute Chronic Myeloge... Myelodysplastic... Non-Hodgkin Lym... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Regulatory T-ce... Conventional T-... Melphalan Thiotepa Fludarabine Anti-thymocyte ... CliniMACS CD34 ... | - 60 Years | Stanford University | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation | NCT01243489 | Chronic Myeloge... | compliance supp... | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Nilotinib, for Patients With CML-CP or CML-AP | NCT04518644 | Chronic Myeloge... | Nilotinib | 18 Years - 99 Years | Novartis | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | NCT01885897 | Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Lymphoma Myeloma Chronic Lymphoc... Chronic Myeloge... | ALT-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Phase I Study of Milatuzumab for Graft Versus Host Disease | NCT01663766 | GVHD (Acute or ... Acute Myeloid o... Myelodysplastic... Chronic Myeloge... Multiple Myelom... Non-Hodgekin Ly... Chronic Lymphoc... | milatuzumab | 18 Years - | Gilead Sciences | |
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | NCT00433745 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1 Peptide Vac... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia | NCT00001623 | Graft vs Host D... Hematologic Neo... Leukemia Multiple Myelom... Myelodysplastic... | Allogeneic Bone... | 10 Years - 55 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy | NCT00264160 | Leukemia, Myelo... | AMN107 | 18 Years - | Novartis | |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | NCT02259348 | Acute Lymphobla... Acute Myeloid L... Myeloid Sarcoma Chronic Myeloge... Juvenile Myelom... Myelodysplastic... Non-Hodgkin Lym... | Cyclophosphamid... Fludarabine G-CSF Interleukin-2 Melphalan Thiotepa Rituximab Natural killer ... T-cell depleted... CD45RA-depleted... | - 21 Years | St. Jude Children's Research Hospital | |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | NCT02730299 | Hematological M... Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Lymphoma Acute Leukemia | NiCord® (omidub... Cord Blood Unit | 12 Years - 65 Years | Gamida Cell ltd | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation | NCT01243489 | Chronic Myeloge... | compliance supp... | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation | NCT00672152 | Acute Myelogeno... Chronic Myeloge... Acute Lymphobla... Myelodysplastic... B Cell Malignan... | WT1 derived pep... | 18 Years - | Duke University | |
| Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | NCT01413568 | Acute Myeloid L... Adult Acute Lym... Chronic Myeloge... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... Myeloproliferat... | POL6326 Leukapheresis PBSC Transplant | 18 Years - 75 Years | Polyphor Ltd. | |
| Unrelated Umbilical Cord Blood (UBC)Transplantation | NCT01768845 | Chronic Myeloge... Acute Myelogeno... Myelodysplastic... Multiple Myelom... Hodgkin Lymphom... Non-Hodgkin Lym... Chronic Lymphoc... Acute Lymphocyt... Severe Aplastic... | umbilical cord ... | 16 Years - 70 Years | West Virginia University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
